Autoimmune hemolytic anemia, warm type

Last reviewed March 21, 2026

🖨 Print for my doctor Advocacy Hub →

ORPHA:90033D59.1

Who is this for?

Show terms as

6Active trials 4Specialists 8Treatment centers

Where are you in your journey?

ℹ

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.

Report missing data

Overview

Also known as:

Warm AIHA wAHA wAIHA

Clinical phenotype terms— hover any for plain English:

Autoimmune hemolytic anemiaHP:0001890HemoglobinuriaHP:0003641MicrospherocytosisHP:0004835Lymphoproliferative disorderHP:0005523Unconjugated hyperbilirubinemiaHP:0008282Decreased hemoglobin concentrationHP:0020062Reduced haptoglobin levelHP:0020181Positive direct antiglobulin testHP:0032366

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events

Apr 2026Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

Novartis Pharmaceuticals — PHASE2

TrialRECRUITING

Aug 2025A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

Sanofi — PHASE3

TrialRECRUITING

Nov 2023Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA

Chen Miao — PHASE2

TrialRECRUITING

Sep 2023A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)

Zenas BioPharma (USA), LLC — PHASE3

TrialACTIVE NOT RECRUITING

Jun 2023Sirolimus in the Treatment of Refractory/Relapsed wAIHA

Peking Union Medical College Hospital — NA

TrialRECRUITING

Dec 2022A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Novartis Pharmaceuticals — PHASE3

TrialACTIVE NOT RECRUITING

Dec 2021Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

Sanofi — PHASE2

TrialACTIVE NOT RECRUITING

Mar 2021Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

City of Hope Medical Center — PHASE2

TrialACTIVE NOT RECRUITING

Oct 2019A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Rigel Pharmaceuticals — PHASE3

TrialENROLLING BY INVITATION

Aug 2019Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

Janssen Research & Development, LLC — PHASE2, PHASE3

TrialACTIVE NOT RECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Autoimmune hemolytic anemia, warm type.

6 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

6 recruitingView all trials with filters →

Phase 31 trial

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

Phase 3

Active

PI: Novartis Pharmaceuticals (Novartis Pharmaceuticals) · Sites: Farmington Hills, Michigan; Minneapolis, Minnesota +51 more · Age: 18–100 yrs

Phase 24 trials

Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia

Phase 2

Active

PI: Alexey Danilov (City of Hope Medical Center) · Sites: Duarte, California · Age: 18–99 yrs

Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA

Phase 2

Actively Recruiting

· Sites: Beijing, Beijing Municipality · Age: 18–90 yrs

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

Phase 2

Actively Recruiting

PI: Novartis Pharmaceuticals (Novartis Pharmaceuticals) · Sites: Roeselare, West-Vlaanderen; Guangzhou, Guangdong +7 more · Age: 18–100 yrs

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

Phase 2

Active

· Sites: Cerritos, California; Cerritos, California +25 more · Age: 18–99 yrs

N/A1 trial

Sirolimus in the Treatment of Refractory/Relapsed wAIHA

N/A

Actively Recruiting

· Sites: Beijing, Beijing Municipality · Age: 18–90 yrs

Specialists

4 foundView all specialists →

AD

Alexey Danilov

DUARTE, CA

Specialist

B-cell chronic lymphocytic leukemia

PI on 2 active trials

Active trials Directions Travel grants

HM

Heng Mei

Specialist

Acute myeloid leukemia Autoimmune thrombocytopenia T-cell prolymphocytic leukemia

PI on 4 active trials76 Autoimmune hemolytic anemia, warm type publications

Active trials Directions Travel grants

KM

Kathleen Butler, MD

Specialist

Alopecia Coronary artery congenital malformation Disorder of purine metabolism+4 more

PI on 9 active trials

Active trials Directions Travel grants

PM

PierMannuccio Mannucci, MD

Specialist

Autoimmune hemolytic anemia, cold type

PI on 1 active trial

Active trials Directions Travel grants

Treatment Centers

8 centers

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Autoimmune hemolytic anemia, warm type.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Autoimmune hemolytic anemia, warm typeForum →

No community posts yet. Be the first to share your experience with Autoimmune hemolytic anemia, warm type.

Start the conversation →

Latest news about Autoimmune hemolytic anemia, warm type

Disease timeline:

New recruiting trial: A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

A new clinical trial is recruiting patients for Autoimmune hemolytic anemia, warm type

New recruiting trial: Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

A new clinical trial is recruiting patients for Autoimmune hemolytic anemia, warm type

New recruiting trial: Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA

A new clinical trial is recruiting patients for Autoimmune hemolytic anemia, warm type

New recruiting trial: Sirolimus in the Treatment of Refractory/Relapsed wAIHA

A new clinical trial is recruiting patients for Autoimmune hemolytic anemia, warm type

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Autoimmune hemolytic anemia, warm type

Are there clinical trials for Autoimmune hemolytic anemia, warm type?

Yes — 6 recruiting clinical trials are currently listed for Autoimmune hemolytic anemia, warm type on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Autoimmune hemolytic anemia, warm type?

4 specialists and care centers treating Autoimmune hemolytic anemia, warm type are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.